Company Overview and News

19
10 Blue-Chip Consumer Stocks to Buy | InvestorPlace

2018-06-15 investorplace
That means when the economic numbers are on the rise, the U.S. consumer is also on the rise. The Federal Reserve just raised interest rates for the second time this year and it says it will likely raise it two more times in 2018. And instead of rocking the market, the market took it as a positive sign that the 10-year economic doldrums may be at an end. I’ll take it one step at a time.
LW PLNT MMYT PRMW EL LGIH NUS HEAR SAM CENT

55
4 Stocks That Doubled On My Watch

2018-06-12 seekingalpha
Missing out on winning stocks can serve as great moments to reflect on how to invest.
PLNT AAXN CMG

2
PLNT / Planet Fitness, Inc. / Bank of New York Mellon Corp - null (Passive Investment)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* NAME OF ISSUER: Planet Fitness, Inc. TITLE OF CLASS OF SECURITIES: Common Stock CUSIP NUMBER: 72703H101 DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: May 31, 2018 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosur
PLNT

2
PLNT / Planet Fitness, Inc. / Bank of New York Mellon Corp - null (Passive Investment)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* NAME OF ISSUER: Planet Fitness, Inc. TITLE OF CLASS OF SECURITIES: Common Stock CUSIP NUMBER: 72703H101 DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: May 31, 2018 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosur
PLNT

14
Solid Income In Good And Bad Times

2018-06-07 seekingalpha
If we had to summarize the investment thesis for Realty Income (NYSE:O) in one short sentence, it would be along the lines of: “Solid income in good, and bad times”.
PLNT YUM O.PRF O WBA DG OPRF

48
Buy These 7 Small-Cap Stocks for Their Emerging Opportunities

2018-06-04 investorplace
Both the Russell 2000 and S&P 600 indices hit all-time highs last week as investors continued to jump on the small-cap bandwagon. Can anything stop small-cap stocks from moving higher over the remainder of 2018?
Z CPB PRAA WTW PLNT BRK.A ZG 73640QAB1 CVCO WIFI MED PETQ

2
How Planet Fitness founder Chris Rondeau created the fastest growing gym chain in the US

2018-06-03 telegraph.co.uk
Planet Fitness is America’s fastest-growing health club company with gyms in all 50 states and a foothold in Canada, Mexico, the Dominican Republic and Panama.
PLNT XKE

6
Auditor Ratification: The Biggest (Almost) Losers : TheCorporateCounsel.net Blog

2018-05-30 thecorporatecounsel.net
Broc recently blogged about the rough sledding that GE experienced when it went to shareholders for ratification of its appointment of KPMG – “no” votes represented more than 35% of the votes cast on the proposal at this year’s annual meeting. However, this “Audit Analytics” blog says that the GE result didn’t even manage to crack the ‘Top 3’ no-vote getters for the three years ended December 31, 2017.
PLNT PLYM.PRA RMTI PLYM

49
Anticipating Fitbit's Next Moves

2018-05-22 seekingalpha
At FIT's current trading level, compared with its assets, I view it as a call option with limited downside.
PLNT FIT GLUU

2
Why early retirement is all it’s cracked up to be - MarketWatch

2018-05-15 marketwatch
Sometimes, the stuff that people say about early retirement (and early retirees) is terrible. It is assumed that early retirement is the end of productive life and that unless we’re swimming in millions in cold hard cash, early retirement will eat us alive.
PLNT

4
No 'Fooling' Around With This Top Performing Small Cap Growth Stock Model

2018-05-15 seekingalpha
Small cap stocks offer investors lots of long term opportunity, but finding a way to filter out the best stocks is how long term alpha be achieved.
PLNT ETFC RMR NOAH JOUT

2
Planet Fitness's (PLNT) CEO Chris Rondeau on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good afternoon. My name is Sarah, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Planet Fitness First Quarter 2018 Earnings Call. [Operator Instructions] Thank you.
PLNT

5
PLNT / Planet Fitness, Inc. S-8

2018-05-11 sec.gov
S-8 As filed with the Securities and Exchange Commission on May 11, 2018 Registration No. 333-
PLNT

2
Alaris Royalty's (ALARF) CEO Steve King on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Alaris Royalty Corp. (OTC:ALARF) Q1 2018 Results Earnings Conference Call May 8, 2018 11:00 AM ET
PLNT AD ALARF

9
Wheeler Real Estate Investment's (WHLR) CEO Dave Kelly on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Wheeler Real Estate Investment Trust (NASDAQ:WHLR) Q1 2018 Earnings Conference Call May 9, 2018 10:00 AM ET
PLNT WHLRD TSCO WHLRW WHLR WHIR WHLRP

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to PLNT / Planet Fitness, Inc. on message board site Silicon Investor.

PLNT - RUMORED SHELL BUYOUT
CUSIP: 72703H101